Navigation Links
Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines

HUNTINGTON BEACH, Calif., and AMSTERDAM, Netherlands, Sept. 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint(R), has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare Improvement CBO. The CBO guidelines, which cover all areas of healthcare and have an important role to play in the improvement of the quality of patient treatment and care, were drafted in collaboration with the Dutch Association of Comprehensive Cancer Centers (ACCC) and the Dutch National Breast Cancer Consultation Group (NABON).

The inclusion of MammaPrint in CBO's updated clinical practice guidelines represents a significant step forward for the role of molecular diagnostics in breast cancer treatment planning. Specifically, the new guidelines acknowledge the prognostic power of MammaPrint in general and highlight its ability to identify subgroups of untreated node negative patients as having a good or poor prognosis. The test also allows physicians and patients to determine with which therapy, if any, to address each individual patient's risk profile, ultimately providing a significant benefit of more personalized medicine. The Dutch guideline committee also encouraged physicians to enter patients into the MINDACT trial to allow establishing additional knowledge.

"We are delighted that MammaPrint has been included in the CBO guidelines," said Bernhard Sixt, Ph.D., president and chief executive officer of Agendia. "With a very high accuracy, MammaPrint identifies patients who have a risk of developing metastases within five to seven years after surgery. Therefore, the test is a very powerful tool that allows physicians to assess the rationale of adjuvant chemotherapy, which has been shown to be effective in reducing these early events in a meta-analysis of studies that included 30,000 patients."

The Dutch Institute for Healthcare Improvement CBO was founded in 1979 by the Dutch Association of Medical Specialists and Dutch Association of Chief Medical Officers, as an independent, not-for-profit foundation devoted to improving the quality of patient care in The Netherlands. The guidelines are available online at and are published in the September/October issue of the Journal of the Dutch Association of Medical Oncology.

About MammaPrint(R)

MammaPrint(R) laboratory service is the first FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint(R) measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint(R) test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result serves to help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint(R) tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia is a world leader in molecular cancer diagnostics. The company markets four products based on its breakthrough platform for tumor gene expression profiling, and has several new diagnostic tests under development. Agendia was the first company to receive FDA clearance for a breast cancer test, MammaPrint(R) that predicts the risk of breast cancer recurrence. In addition, the company collaborates with pharma companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information on Agendia, please visit


U.S. Media Contact:

Kelly Connor

Vice President

Ogilvy Public Relations Worldwide

+1.212.880.5328 Office

+1.609.221.5785 Mobile

EU and non-US Media:

Hans Herklots

Head of Corporate Communications


+31.20.462.1557 Office

+31.620.083.509 Mobile

SOURCE Agendia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
2. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
3. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
4. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
5. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
6. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
7. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
8. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
10. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
Breaking Medicine News(10 mins):